If each stage of testing costs proportionally more (and thus can be applied to proportionally fewer drugs in parallel), each increment of improvement in drug screening accuracy has *exponential* improvements in cost-per-successful-drug-candidate.
-
-
Show this thread
-
Yet, "better drug discovery platforms" are perceived (at least by traditional pharma and clinical-stage biotech investors) as low-value, risky, and unserious. Pharma business development execs I've talked to have said that their companies don't license new screening tech at all!
Show this thread -
Unless I'm misinformed, this isn't a case where novel screening methods are mistrusted because they have a poor track record.
Show this thread
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.